Benzinga | Jun 10, 2021 04:32PM EDT

aTyr Pharma Highlights Presentation Of Second Anti-NRP2 Antibody Of Antibody Engineering & Therapeutics Europe Virtual

Preclinical candidate is second to demonstrate selective blocking ability from in-house panel of antibodies targeting NRP2.

aNRP2-14 blocks Semaphorin 3F/NRP2 signaling pathways which are implicated in immune-mediated diseases.

SAN DIEGO, June 10, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (NASDAQ:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the presentation of a poster at the Antibody Engineering & Therapeutics Europe Virtual conference which was held June 8 -- 10, 2021. The abstract and poster are available on the conference website.

The poster presents preclinical findings demonstrating in vitro and in vivo proof-of-concept that the anti-Neuropilin-2 (NRP2) antibody, aNRP2-14, is a high affinity, selective blocker of the Semaphorin 3F/NRP2 interaction. Class 3 Semaphorins are an important set of NRP2 ligands, with recent data implicating their role in sustaining chronic inflammation.

Details of the abstract and poster presentation are as follows:

Title: Engineering an anti-Neuropilin-2 (NRP2) antibody that selectively blocks NRP2 interactions with Semaphorin and Plexin

Authors: Kaitlyn Rauch, Luke Burman, Yanyan Geng, Liting Zhai, Yeeting E. Chong, Ann Menefee, Kristina Hamel, Zhiwen Xu, Nathaniel Bloom, Lauren Guy, Matt Seikkula, Christoph Burkart, Leslie A. Nangle. aTyr Pharma, San Diego, CA, Pangu Biopharma, Hong Kong.

Date: June 8 -- 10, 2021